From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Crucell N.V.
Privately held naamloze vennootschap; subsidiary
HeadquartersLeiden, Netherlands
Key people
Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
ProductsVaccines and antibodies
OwnerJohnson & Johnson

Crucell is a biotechnology company specializing in vaccines and biopharmaceutical technologies.

In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2] and delisting the company from stock exchanges two months later.[3]


  1. ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
  2. ^ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
  3. ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.

External links[edit]